Table 1 Characteristics of the RCTs and patients included in the meta-analysis
Number | Author/year | NCT Number | Nation | Study phase | Interventions | Sample size | Median age (P/C) years | Median treatment duration (P/C) | Cancer type | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
PARP group | Control group | PARP inhibitor group | Control group | ||||||||
1 | Kaye [18] et.al 2011 | NCT00628251 | United States, Australia, etc | II | Olaparib (400Â mg/day) | Liposomal doxorubicin | 32 | 32 | 58.5/53 | NA | Ovarian cancer |
Olaparib (800Â mg/day) | 32 | 53.5/53 | NA | Ovarian cancer | |||||||
2 | Ledermann [19] et.al 2012 | NCT00753545 | United States, Austria, etc | II | Olaparib (800Â mg/day) | Placebo | 136 | 128 | 58/59 | 206.5/141Â days | Ovarian cancer |
3 | Pusztai [20] et.al 2021 | NCT01042379 | United States | II | Olaparib (200 mg/day) +  Durvalumab + Paclitaxel +  Doxorubicin +  Cyclophosphamide | Paclitaxel + Doxorubicin + Cyclophosphamide | 73 | 299 | 46/48 | NA | Breast cancer |
4 | Rugo [21] et.al 2016 | II | Veliparib (100 mg/day) +  Carboplatin + Paclitaxel | Carboplatin + Paclitaxel | 72 | 44 | 48.5/47.5 | 182/165 days | Breast Cancer | ||
5 | Novello [22] et.al 2014 | NCT01086254 | France, Germany, etc | II | Iniparib (11.2 mg/kg/week) + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin | 78 | 39 | 59/58 | 15/13.9 weeks | Lung cancer |
6 | Han [23] et.al 2018 | NCT01506609 | United States, Australia, etc | II | Veliparib (240 mg/day) +  Carboplatin + Paclitaxel | Placebo + Carboplatin +  Paclitaxel | 93 | 96 | 44/46 | 36/30 weeks | Breast Cancer |
Veliparib (80 mg/day) +  Temozolomide | 93 | 46/46 | 18/30 weeks | Breast Cancer | |||||||
7 | Hussain [24] et.al 2017 | NCT01576172 | United States | II | Veliparib (600 mg/day) + Abiraterone acetate + Prednisone | Abiraterone acetate + Prednisone | 79 | 74 | 68/69 | 36/36 weeks | Prostate Cancer |
8 | Owonikoko [25] et.al 2020 | NCT01642251 | United States | II | Veliparib (200 mg/day) +  Etoposide + Cisplatin | Placebo + Etoposide +  Cisplatin | 66 | 66 | 66/64 | NA | Lung Cancer |
9 | Fennell [26] et.al 2022 | NCT01788332 | United Kingdom | II | Olaparib (600Â mg/day) | Placebo | 31 | 38 | 65/63 | 12/12Â weeks | Lung cancer |
10 | Banerjee [27] et.al 2021 | NCT01844986 | United States, Canada, etc | III | Olaparib (600Â mg/day) | Placebo | 260 | 130 | NA | 24.6/13.9Â months | Ovarian cancer |
11 | Mirza [28] et.al 2016 | NCT01847274 | United States, Italy, etc | III | Niraparib (300Â mg/day) | Placebo | 367 | 179 | NA | NA | Ovarian cancer |
12 | Bang [29] et.al 2017 | NCT01924533 | China, Japan, etc | III | Olaparib (200 mg/day) + Paclitaxel | Placebo + Paclitaxel | 262 | 259 | 58/59 | 73.5/59 days | Gastric cancer |
13 | Ledermann [30] et.al 2021 | NCT01968213 | United States, Australia, etc | III | Rucaparib (1200Â mg/day) | Placebo | 372 | 189 | 61/62 | 8.3/5.5Â months | Ovarian cancer |
14 | Clarke [31] et.al 2018 | NCT01972217 | United States, Canada, etc | II | Olaparib (600 mg/day) + Abiraterone | Pacebo + Abiraterone | 71 | 71 | 70/67 | 309/253 days | Prostate cancer |
15 | Loibl [32] et.al 2018 | NCT02032277 | United States, Australia, etc | III | Veliparib (100 mg/day) + Paclitaxe + Carboplatin | Veliparib placebo + Paclitaxel +  Carboplatin | 313 | 158 | 51/49 | 89/85.5 days | Breast cancer |
Veliparib placebo + Paclitaxel +  Carboplatin placebo | 157 | 51/50 | 89/84 days | Breast cancer | |||||||
16 | Diéras [33] et.al.2020 | NCT02163694 | United States, Australia, etc | III | Veliparib (240 mg/day) + Carboplatin + Paclitaxel | Placebo + Carboplatin + Paclitaxel | 336 | 171 | 47/45 | NA | Breast cancer |
17 | Golan [34] et.al 2020 | NCT02184195 | United States, Canada, etc | III | Olaparib (600Â mg/day) | Placebo | 90 | 61 | 57/57 | 6/3.7Â months | Pancreatic Cancer |
18 | Gorbunova [35] et.al 2019 | NCT02305758 | North America, Australia etc | II | Veliparib (400 mg/day) + Irinotecan + Leucovorin  + Fluorouracil infusion ± Bevacizumab | Irinotecan + Leucovorin + Fluorouracil bolus + Fluorouracil infusion ± Bevacizumab | 65 | 65 | 59/64 | NA | Colorectal Cancer |
19 | Liu [36] et.al 2022 | NCT02446600 | United States, Canada, Japan | III | Olaparib (600 mg/day) | Platinum-based chemotherapy | 187 | 167 | NA | NA | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Olaparib (400 mg/day) + Cediranib | 183 | NA | NA | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | |||||||
20 | Coleman [37] et.al 2019 | NCT02470585 | United States, Australia, etc | III | Veliparib (300 mg/day) + Carboplatin + Paclitaxel + followed by veliparib (600 mg or 800 mg/day) maintenance | Placebo + Carboplatin +  Paclitaxel + followed by Placebo maintenance | 377 | 371 | 62/62 | NA | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Veliparib (300 mg/day) + Carboplatin + Paclitaxel + followed by Placebo maintenance | 376 | 62/62 | NA | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | |||||||
21 | Ray-Coquard [38] et.al 2019 | NCT02477644 | Austria, Belgium, etc | III | Olaparib (600 mg/day) +  Bevacizumab | Placebo + Bevacizumab | 535 | 267 | 61/60 | 17.3/15.6 moths | Ovarian cancer |
22 | González-MartÃn [39] et.al 2019 | NCT02655016 | United States, France, etc | III | Niraparib (200 mg or 300 mg/day) | Placebo | 484 | 244 | 62/62 | NA | Ovarian cancer |
23 | Kristeleit [40] et.al 2022 | NCT02855944 | United States, Brazil, etc | III | Rucaparib (1200Â mg/day) | Chemotherapy (administered per institutional guidelines) | 232 | 113 | 58/59 | 7.3/3.6Â months | Ovarian cancer |
24 | Chiorean [41] et.al 2021 | NCT02890355 | United States | II | Veliparib (400 mg/day) +  Irinotecan + Folinic acid + 5-Fluorouracil infusion | Irinotecan + Folinic acid + 5-Fluorouracil bolus +  5-Fluorouracil infusion | 56 | 50 | 67/67 | 8/10 weeks | Pancreatic Cancer |
25 | Bono [42] et.al 2020 | NCT02987543 | United States, Canada, etc | III | Olaparib (600 mg/day) | Physician’s choice of enzalutamide or abiraterone | 256 | 130 | NA | 7.4/3.9 months | Prostate Cancer |
26 | Colombo [43] et.al 2022 | NCT03314740 | Italy | II | Olaparib (600 mg/day) every day + Cediranib every day | Paclitaxel | 41 | 28 | 64.2/62.5 | NA | Ovarian cancer |
Olaparib (600 mg/day) every day + Cediranib 5 days a week | 41 | 59.9/62.5 | NA | Ovarian cancer | |||||||
27 | Ai [44] et.al 2021 | NCT03516084 | China | III | Niraparib (300 or 200Â mg/day) | Placebo | 125 | 60 | NA | 44/42.5Â days | Lung Cancer |
28 | Monk [45] et.al 2022 | NCT03522246 | United States, Australia, etc | III | Rucaparib (1200Â mg/day) | Placebo | 425 | 110 | 61/61 | 14.7/9.9Â month | Ovarian cancer |
29 | Wu [46] et.al 2020 | NCT03705156 | China | III | Niraparib (300Â mg or 200Â mg/day) | Placebo | 177 | 88 | 53/55 | 369/171Â days | Ovarian cancer |
30 | Woll [47] et.al 2022 | / | United Kingdom | II | Olaparib (300Â mg twice a day) | Placebo | 73 | 74 | 66/64 | 8/8Â weeks | Lung cancer |
Olaparib ( 200Â mg three times a day) | Placebo | 73 | 63/64 | 19/8Â weeks | Lung cancer | ||||||
31 | Sun [48] et.al 2022 | / | China | II | Olaparib (400 mg/day) + Bevacizumab | Albumin-bound paclitaxel + Bevacizumab | 42 | 42 | NA | NA | Ovarian cancer |
32 | O’Reilly [49] et.al 2020 | / | United States, Canada, Israel | II | Veliparib (160 mg/day) +  Cisplatin + Gemcitabine | Cisplatin + Gemcitabine | 27 | 23 | 64/63 | NA | Pancreas Adenocarcinoma |